Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.

By L. Klotz, Liying Zhang, Adam Lam, R. Nam, A. Mamedov, A. Loblaw. Journal of Clinical Oncology, 2010

1,113 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Statistics and Probability

View Paper: https://www.semanticscholar.org/paper/e08c145846ff2ba7f34a2d0c4a6e201aebfe2e85

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. M. Hallek
2. N. Mottet
3. Thomas Wiegel
4. Steven Joniau
5. J. Bellmunt
6. Michel Bolla
7. V. Matveev
8. F. Zattoni

In Statistics and Probability

1. M. Hallek

Citations in the corpus

• Prostate Cancer (2018, methodology): “Table 4: Criteria for Selection, Monitoring and Intervention of Active Surveillance Patients [2, 11]    Parameters Inclusion Criteria - all mandatory - Follow-Up Intervention Criteria -one criterion mandatory - PSA ≤ 10 ng / ml     Every 3 months over 2 years, then every 6 months PSA DT2 < 3 years G”
• EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. (2011, background): “According to recent data, men with low-risk PCa and a life expectancy >10 yr are good candidates for AS, and only about 30% of men will require delayed radical intervention [44].”
• Guidelines on Prostate Cancer (2013, background): “(17) 453 70 Gleason < 6, PSA < 10 ng/mL (up to 1999: Gleason < 3+4, PSA < 15 ng/mL), < 3 biopsies +, < 50% each core”
• Active surveillance for prostate cancer: a systematic review of the literature. (2012, methodology): “15 University of Toronto [9] NS 10 3 + 3 NR NR – UCSF [10] T2a 10 3 + 3 33% 50% – ERSPC (PRIAS criteria) [11] T2a 10 3 + 3 2 NR PSA DT 0.”
• EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. (2017, background): “Active treatment may also be triggered upon a patient’s request [44].”
• EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. (2014, background): “[48], included 450 patients with clinical stage T1c or T2a, PSA <10 ng/ml, and Gleason score 6 (PSA <15), with patients >70 yr of age having a Gleason score 7 (3 + 4).”
• Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. (2015, methodology): “50%.(3) That included many patients from the late 1990s.”
• Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. (2011, background): “Furthermore, aggregate data from published surveillance cohorts have demonstrated prostate cancer–specific survival greater than 99% at a median follow-up of 43 months.(12) Nonetheless, it has been shown that even 10 years is not an adequate time frame for the evaluation of prostate cancer–specific ”